SCHEMBL6323243

SCHEMBL6323243

CCCCC(CC)CNC(=O)c1c(-c2sccc2C)noc1N

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.48
TSHR P16473 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
GLA P06280 1/20 0.48
POLB P06746 3/20 0.39
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MAPK1 P28482 1/20 0.39
TP53 P04637 1/20 0.36
ALDH1A1 P00352 3/20 0.35
KMT2A Q03164 2/20 0.35
P2RX7 Q99572 1/20 0.35
MAP4K1 Q92918 1/20 0.33
GAA P10253 1/20 0.33
GABRA5 P31644 1/20 0.33
HRH4 Q9H3N8 1/20 0.32
HRH3 Q9Y5N1 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324184 0.85 ALDH1A1 (0.44) HTTTSHRL3MBTL1POLBLMNA
SCHEMBL6317656 0.84 GAA (0.42) HTTL3MBTL1POLBLMNASMN1; SMN2
SCHEMBL6322906 0.84 GAA (0.42) HTTPOLBLMNASMN1; SMN2TP53
SCHEMBL6316236 0.83 GAA (0.41) L3MBTL1POLBLMNASMN1; SMN2TP53
SCHEMBL6317489 0.83 GAA (0.41) L3MBTL1POLBLMNASMN1; SMN2TP53
SCHEMBL6324005 0.83 GAA (0.41) L3MBTL1POLBLMNASMN1; SMN2TP53
SCHEMBL6321043 0.82 HTT (0.45) HTTTSHRL3MBTL1GLAPOLB
SCHEMBL6322613 0.80 TSHR (0.43) HTTTSHRL3MBTL1GLAPOLB
SCHEMBL6622123 0.80 POLB (0.39) TSHRGLAPOLBLMNASMN1; SMN2
SCHEMBL6316911 0.80 MEN1 (0.45) HTTTSHRL3MBTL1GLAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 HTT 2134/4885TSHR 3971/4885L3MBTL1 4176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.